E-Pharmacies in India: The Regulatory Limbo Every Clinic and Pharmacist Should Understand

Here is a fact that surprises most people, including many pharmacists and clinic owners: India has never actually finalised a specific law governing online pharmacies. The draft rules meant to do exactly that were first published in August 2018. As of mid-2026, they remain unnotified — nearly eight years later — while multiple High Courts have issued conflicting interim orders, and platforms serving millions of customers continue operating in a genuinely unsettled legal space. This article explains how this happened and what it means practically.

Where This Started: The 2018 Draft Rules

In August 2018, the Ministry of Health and Family Welfare published the Drugs and Cosmetics (Amendment) Rules, 2018 — commonly called the Draft E-Pharmacy Rules — for public comment. Under this proposal, anyone wishing to distribute, sell, stock, or offer medicines for sale by electronic means would need to obtain a registration certificate (valid for three years) from the licensing authority. The draft rules also proposed specific restrictions — barring e-pharmacies from selling narcotic drugs, tranquilisers, and Schedule X drugs, and prohibiting e-pharmacy advertising. The government received public comments on the draft. It has not, as of this writing, notified a final version.

The Delhi High Court Litigation: A Ban That Was Never Really Enforced

In 2018, Dr. Zaheer Ahmed filed a public interest litigation in the Delhi High Court, arguing that online drug sales violated the Drugs and Cosmetics Act and Rules as they then stood. On December 12, 2018, a Delhi High Court division bench issued an interim order effectively banning the online sale of medicines without a valid licence, pending final rules. In practice, this order was never comprehensively enforced against the growing e-pharmacy industry — platforms continued operating, raised significant funding, and some acquired legacy healthcare businesses including diagnostics chains, even as the interim restriction technically remained in place. This gap between the formal legal position and actual market behaviour is the defining feature of India’s e-pharmacy landscape.

The Madras High Court’s More Permissive Position

A parallel case unfolded in Tamil Nadu. After an initial single-judge ruling also favouring restriction, a Madras High Court division bench ultimately took a notably different position, explicitly allowing the online sale of drugs, on the specific condition that any such sale be routed through licensed druggists and chemists only. This effectively endorsed the lawfulness of e-pharmacies and e-marketplaces operating through properly licensed pharmacy partners — directly at odds with the more restrictive tenor of the Delhi proceedings, and creating exactly the kind of jurisdictional inconsistency that has made this area so difficult for the industry, regulators, and patients alike to navigate with confidence.

A Pattern of Repeated Deadlines, Repeatedly Missed

The Delhi High Court has, over several years, repeatedly ordered the central government to finalise a regulatory framework, and the central government has repeatedly asked for more time:

• March 2023: the government told the Court a proposal was “under consideration” and more time was needed.
• May 2023: the Court granted a further six weeks for the government to report on stakeholder consultations.
• November 2023: the Court directed the government to frame a policy within eight weeks, explicitly noting the draft rules had already been pending for over five years.
• 2024: after the eight-week deadline passed without a finalised policy, the Court required a joint secretary to personally appear before it, and separately warned that if a draft policy was not prepared before the next hearing date, the Court would have no option but to proceed with the matter itself.
• 2026: as of this writing, the Delhi High Court has continued granting further extensions — most recently a further six weeks — while awaiting the outcome of ongoing stakeholder consultations.

This pattern — a genuine, court-acknowledged regulatory gap persisting across multiple governments and years — is unusual even by the standards of slow Indian regulatory processes, and reflects how genuinely difficult it has been to reconcile the competing interests involved: traditional pharmacy associations pushing for restriction, e-pharmacy platforms and their investors pushing for a clear operating framework, and patient-access advocates concerned about disruption to home delivery, particularly for chronic-condition medication.

CDSCO’s Direct Enforcement Attempts

Separately from the court proceedings, the Central Drugs Standard Control Organization has taken its own direct action at points — in February 2023, CDSCO issued show-cause notices to 20 online pharmacy platforms, including major names like Flipkart, Amazon, and Tata 1mg, alleging they were facilitating the sale of medicines that require a valid prescription without adequately verifying one. These platforms have generally responded by arguing they function only as an intermediary connecting consumers to licensed pharmacies, rather than as the seller themselves — a legal characterisation question (intermediary status under the Information Technology Act, 2000, versus direct seller obligations under the Consumer Protection (E-Commerce) Rules, 2020) that has itself become a live area of litigation, including a 2025 Delhi High Court ruling in IndiaMART v. CDSCO addressing exactly this intermediary-classification question.

What This Means Practically for a Clinic or Pharmacist Today

1. The underlying Drugs and Cosmetics Act and Rules still apply to any sale of medicine, online or offline — a valid drug licence, and Schedule H/H1/X prescription requirements, are not suspended simply because rules specific to e-pharmacies remain unfinalised.
2. A pharmacist or clinic considering an online sales or delivery model should ensure any such arrangement is genuinely routed through a validly licensed pharmacy, consistent with the position the Madras High Court has taken, rather than assuming an unregulated space means no rules apply at all.
3. Given the genuine jurisdictional inconsistency between Delhi and Madras High Court positions, and the ongoing, unresolved central litigation, any business model built around online medicine sale carries real, acknowledged legal uncertainty that should be assessed with current legal advice, not assumptions based on how the market appears to be operating in practice.
4. Prescription verification remains a genuine compliance obligation regardless of the sales channel — platforms and pharmacies facing CDSCO scrutiny have specifically been challenged on inadequate prescription verification, which is squarely within existing law, not a gap awaiting new e-pharmacy-specific rules.
5. Watch for the outcome of the ongoing Delhi High Court proceedings and any eventual final notification of e-pharmacy rules, since this could materially change the compliance landscape once it happens, after nearly eight years of anticipation.

Why This Matters Beyond Pharmacy Operators

This prolonged regulatory gap is directly relevant to clinics and doctors too, not just pharmacy operators — as e-prescription workflows (covered elsewhere in this series) and telemedicine consultations increasingly route patients toward online medicine fulfilment, doctors and clinics should understand that the pharmacy end of that patient journey is operating in a genuinely unsettled legal environment, distinct from the more settled legal position on e-prescriptions themselves. A doctor recommending or partnering with a specific online pharmacy service should be aware of this underlying uncertainty when making that recommendation.

Frequently Asked Questions

Is it currently legal to buy medicine online in India?

The legal position is genuinely unsettled — the Delhi High Court’s 2018 interim order technically restricts unlicensed online sale, while the Madras High Court has permitted online sale routed through licensed pharmacies; in practice, the industry continues operating at meaningful scale while final rules remain unnotified.

Have the Draft E-Pharmacy Rules of 2018 ever been finalised?

No. As of this writing, nearly eight years after being published for comment, they remain in draft, unnotified form, despite repeated Delhi High Court directions to the central government to finalise a framework.

Can an e-pharmacy platform sell Schedule X or narcotic medications?

The 2018 draft rules specifically proposed barring e-pharmacies from selling narcotic drugs, tranquilisers, and Schedule X drugs; even absent final notification of those specific rules, the underlying NDPS Act and Drugs and Cosmetics Rules restrictions on these categories, covered elsewhere in this series, continue to apply regardless of sales channel.

Do e-commerce platforms selling medicines bear the same responsibility as a pharmacy?

This is a genuinely contested legal question — platforms have generally argued they are intermediaries rather than direct sellers, while regulators and some court rulings have pushed back on that characterisation, and this remains an active area of litigation.

What should a clinic do if considering a partnership with an online pharmacy for patient convenience?

Confirm the online pharmacy routes sales through validly licensed pharmacies with genuine prescription verification, and seek current legal advice given the acknowledged regulatory uncertainty, rather than assuming market presence alone indicates settled legality.

Researched Sources

1. Business Standard — Delhi High Court Grants Centre Six Weeks on E-Pharmacy Draft Rules Consultations
2. Lexology (IndusLaw) — Madras High Court Greenlights Online Sale of Drugs and Medical Devices in India
3. SCC Times — Regulation of Online Pharmacies in India
4. International Bar Association — E-Pharmacies and the Law: An Uneasy Balance
5. Spice Route Legal — Regulation of E-Pharmacies in India

Disclaimer

This article is for general informational and educational purposes and reflects the e-pharmacy regulatory landscape as understood at the time of writing; this remains an actively litigated and unresolved area of law. It is not legal advice; pharmacists, clinics, and businesses should consult a qualified healthcare and technology lawyer before undertaking any online medicine sale or partnership activity.